KR-102962318-B1 - Composition for preventing or treating of obesity comprising Lentinus edodes mycelial culture

Abstract

The present invention relates to a composition for preventing or treating obesity comprising a shiitake mushroom mycelium culture as an active ingredient. By confirming that administering the shiitake mushroom mycelium culture reduces weight gain caused by a high-fat diet and reduces blood triglycerides, obesity can be prevented and treated using the shiitake mushroom mycelium culture.

Inventors

• 윤미영
• 최화정
• 김선형

Assignees

• 광주여자대학교 산학협력단

Dates

Publication Date

20260507

Application Date

20220715

Claims (7)

1. In a pharmaceutical composition for the prevention or treatment of obesity comprising a shiitake mushroom mycelial culture as an active ingredient, A pharmaceutical composition for preventing or treating obesity, characterized in that the shiitake mushroom mycelium culture is a culture obtained by culturing for 5 to 10 days in a medium mixed with barley and rice bran in a weight ratio of 20:1.
2. delete
3. delete
4. In paragraph 1, A pharmaceutical composition for the prevention or treatment of obesity, characterized in that the above composition is any one of the formulations selected from the group consisting of tablets, capsules, pills, and liquids.
5. In a health functional food for preventing or improving obesity containing shiitake mushroom mycelial culture as an active ingredient, A health functional food for preventing or improving obesity, characterized in that the above shiitake mushroom mycelium culture is a culture obtained by culturing for 5 to 10 days in a medium mixed with barley and rice bran in a weight ratio of 20:1.
6. In paragraph 5, A health functional food for preventing or improving obesity, characterized in that the above shiitake mushroom mycelium is a culture produced by culturing for 5 to 10 days in a medium mixed with barley and rice bran in a weight ratio of 20:1.
7. In paragraph 5, The above-mentioned health functional food is a health functional food for preventing or improving obesity, characterized by being any one formulation selected from the group consisting of tablets, capsules, pills, and liquids.

Description

Composition for preventing or treating obesity comprising Lentinus edodes mycelial culture as an active ingredient The present invention relates to a composition for preventing or treating obesity comprising a shiitake mushroom mycelium culture as an active ingredient. Recently, due to Korea's economic growth and improved living standards, the number of obese patients is increasing as excess calories are accumulated in the body in the form of fat resulting from increased consumption of high-calorie foods and decreased exercise. Obesity, a condition in which an excessive amount of body fat is accumulated in the body, occurs when the calories consumed through food exceed the calories burned through physical activity and are stored as body fat; it is defined as when body fat accounts for 25% or more of body weight for men and 30% or more for women. The primary causes of obesity include genetic factors, environmental factors, and energy metabolism disorders, while syndromic obesity arises from endocrine, hypothalamic, genetic, frontal lobe, and metabolic factors. However, most cases of obesity occur because excess energy is accumulated in the form of body fat when energy expenditure is lower than excessive nutrient intake. In particular, the overweight and obese population has been rapidly increasing during the COVID-19 pandemic. Obesity is considered a chronic disease that must be treated, as it increases the incidence of many conditions, including type 2 diabetes and arteriosclerosis, and raises the associated complications and mortality rates. Currently used treatments for obesity include lifestyle modification methods such as dietary therapy, exercise therapy, and behavioral therapy, as well as drug therapy and surgical treatment. Among these, lifestyle modification should be prioritized; however, since correcting lifestyle habits is not easy and there are limitations to losing weight through diet and exercise alone, drug treatment becomes necessary in many cases. Since thyroid hormones were introduced as a treatment for obesity in the 1890s, many drugs have been attempted, but most were ineffective or their use was discontinued due to side effects. Until recently, the abuse of amphetamines and the combination of fenfluramine and phentermine was banned due to heart valve abnormalities. Meanwhile, mushrooms have long been widely used for medicinal purposes. Mushrooms are also widely consumed as food because they are rich in nutrients such as protein, carbohydrates, vitamins, and minerals (Chang, 2006). Among these, the shiitake mushroom (Lentinus edodes) is cultivated in Southeast Asia and ranks third in cultivation volume and second in utilization rate worldwide. The shiitake mushroom used for food is the fruit body, and substances such as glucan and eritadenine have the effect of lowering blood lipids (Jenkins et al., 2002). β-glucan from shiitake mushroom fruit bodies is known to induce a feeling of satiety in the gastrointestinal tract, thereby reducing food intake, and is effective in delaying nutrient absorption, lowering blood sugar, and reducing cholesterol (Chibata et al., 1969). Furthermore, it was confirmed that the consumption of shiitake mushroom fruit bodies is effective in blood sugar and lipid excretion in a high-cholesterol animal model (Yoon et al., 2011), and the effects of eritadenine from shiitake mushrooms were also confirmed in a high-cholesterol animal model and a coronary artery disease model (Sugiyama et al., 1995). Although shiitake mushroom mycelium was previously unsuitable for edible use in terms of taste, aroma, and harvesting methods, recent studies have reported that it is richer in nutrients and physiologically active components than the fruiting body. Hot water extracts of shiitake mushroom mycelium cultures are known to contain glycoproteins including lentinan (Oba et al., 2009), and have been confirmed to have antioxidant, antibacterial, and anticancer effects. However, the anti-obesity effect of shiitake mushroom mycelium has not yet been directly confirmed. Prior art, Korean Registered Patent No. 1177380 and Korean Published Patent No. 10-2016-0026595, describe an anti-obesity composition characterized by containing corn silk extract, shiitake mushroom extract, green chili pepper extract, and red bean sprout extract as active ingredients, and a functional food composition for anti-obesity, anti-diabetes, and anti-hyperlipidemia purposes containing a mixed extract obtained by mixing extracts of shiitake mushrooms, trifoliate orange, and corn silk, respectively, in a specific mixing ratio as an active ingredient; however, the anti-obesity effect of the shiitake mushroom mycelial culture of the present invention is not described. Furthermore, Korean Registered Patent No. 0898832 describes reducing body weight, subcutaneous fat mass, cell size in adipose tissue, total lipids, triglycerides, and total cholesterol in serum, increasing high-density lipoprotein cholesterol (HDL